Scholars@Duke

Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Publication ,  Journal Article
Ajani, JA; D'Amico, TA; Bentrem, DJ; Chao, J; Corvera, C; Das, P; Denlinger, CS; Enzinger, PC; Fanta, P; Farjah, F; Gerdes, H; Gibson, M ...
Published in: J Natl Compr Canc Netw
July 1, 2019
Published version (DOI) Link to item

Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and adenocarcinoma is most common in North America and Western Europe. Surgery is a major component of treatment of locally advanced resectable esophageal and esophagogastric junction (EGJ) cancer, and randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival. Targeted therapies including trastuzumab, ramucirumab, and pembrolizumab have produced encouraging results in the treatment of patients with advanced or metastatic disease. Multidisciplinary team management is essential for all patients with esophageal and EGJ cancers. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers focuses on recommendations for the management of locally advanced and metastatic adenocarcinoma of the esophagus and EGJ.

Duke Scholars

Thomas Anthony D'Amico
Author Thomas Anthony D'Amico Surgery, Cardiovascular and Thoracic Surgery
Christopher G. Willett
Author Christopher G. Willett Radiation Oncology
Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

10.6004/jnccn.2019.0033

EISSN

1540-1413

Publication Date

July 1, 2019

Volume

17

Issue

7

Start / End Page

855 / 883

Location

United States

Related Subject Headings

  • Ramucirumab
  • Oncology & Carcinogenesis
  • Medical Oncology
  • Humans
  • Guidelines as Topic
  • Esophagogastric Junction
  • Esophageal Neoplasms
  • Combined Modality Therapy
  • Chemoradiotherapy, Adjuvant
  • Antibodies, Monoclonal, Humanized
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ajani, J. A., D’Amico, T. A., Bentrem, D. J., Chao, J., Corvera, C., Das, P., … Pluchino, L. A. (2019). Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 17(7), 855–883. https://doi.org/10.6004/jnccn.2019.0033
Ajani, Jaffer A., Thomas A. D’Amico, David J. Bentrem, Joseph Chao, Carlos Corvera, Prajnan Das, Crystal S. Denlinger, et al. “Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 17, no. 7 (July 1, 2019): 855–83. https://doi.org/10.6004/jnccn.2019.0033.
Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 Jul 1;17(7):855–83.
Ajani, Jaffer A., et al. “Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw, vol. 17, no. 7, July 2019, pp. 855–83. Pubmed, doi:10.6004/jnccn.2019.0033.
Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, Denlinger CS, Enzinger PC, Fanta P, Farjah F, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Leong S, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Paluri RK, Park H, Perry KA, Pimiento J, Poultsides GA, Roses R, Strong VE, Wiesner G, Willett CG, Wright CD, McMillian NR, Pluchino LA. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 Jul 1;17(7):855–883.

Published In

J Natl Compr Canc Netw

DOI

10.6004/jnccn.2019.0033

EISSN

1540-1413

Publication Date

July 1, 2019

Volume

17

Issue

7

Start / End Page

855 / 883

Location

United States

Related Subject Headings

  • Ramucirumab
  • Oncology & Carcinogenesis
  • Medical Oncology
  • Humans
  • Guidelines as Topic
  • Esophagogastric Junction
  • Esophageal Neoplasms
  • Combined Modality Therapy
  • Chemoradiotherapy, Adjuvant
  • Antibodies, Monoclonal, Humanized